Eli Lilly and Company (LLY)
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware of the landmark shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo Nordisk.
Why Eli Lilly Gained 7% On Friday
Eli Lilly saw its biggest gain of 7% in yesterday's trading session since early February, when it jumped 10% on the release of 2025 results. While LLY's gains outstripped peers, it was hardly alone in advancing, with stocks like JNJ and ABBV up too, reflecting a broader momentum for the soft healthcare sector YTD. The company's own developments in segments like oncology and neuroscience set LLY apart from the healthcare pack, though, as they highlight its potential beyond the weight loss market.
Eli Lilly shares rise after EU panel backs expanded use of Jaypirca
Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The positive opinion covers patients regardless of prior treatment with Bruton tyrosine kinase (BTK) inhibitors and marks a step toward broader availability of the drug in the European Union.
Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Abbisko Cayman said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly.
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market as it has done in the United States.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 Reasons to Buy Eli Lilly Stock
Eli Lilly still has a large addressable market in the anti-obesity space. The company boasts a deep pipeline of assets within and outside of its core therapeutic areas.
Prediction: Eli Lilly Will Trade at $1,200 on This Date
Eli Lilly (NYSE:LLY | LLY Price Prediction) just reported a quarter that should have sent bulls into a frenzy.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -1.19% move from the prior day.
